# Clinical Cases: Men's Health

## Case 1: Testosterone Deficiency Syndrome

### Patient Presentation
**Demographics:** 52-year-old male accountant

**Chief Complaint:** "I've lost my energy, my drive, and honestly my confidence over the past two years."

**History of Present Illness:**
The patient presents with a progressive 2-year history of fatigue, decreased libido, erectile dysfunction, and depressed mood. He reports that his energy levels have significantly declined, with afternoon fatigue so severe that he struggles to remain productive at work. He has noticed a loss of motivation and enthusiasm for activities he previously enjoyed, including golf and woodworking.

His sexual complaints include decreased frequency of morning erections (from daily to 1-2 per week), reduced libido, and difficulty maintaining erections during intercourse. He estimates sexual activity has decreased from 2-3 times per week to 1-2 times per month, causing significant relationship strain with his wife.

He has gained approximately 15 kg over the past 3 years despite no major dietary changes, with fat accumulation primarily in the abdominal region. He has noticed decreased muscle mass in his arms and legs and reports that his strength at the gym has plateaued and declined despite consistent training. He also reports increased irritability, difficulty concentrating, and occasional hot flashes.

**Past Medical History:**
- Obstructive sleep apnea (diagnosed 3 years ago, non-compliant with CPAP)
- Type 2 diabetes mellitus (diagnosed 1 year ago)
- Dyslipidemia
- Obesity (BMI 33.2)

**Medications:**
- Metformin 1000 mg BID
- Atorvastatin 20 mg daily
- CPAP prescribed but not using

**Social History:**
- Non-smoker, 2-3 beers on weeknights, more on weekends (estimated 18-20 units/week)
- Sedentary job, attempts gym 2x/week
- Married for 25 years, relationship strain
- Reports high work stress during tax season

**Family History:**
- Father: Type 2 diabetes, myocardial infarction at age 62
- Mother: Osteoporosis
- Brother: Diagnosed with low testosterone at age 48

### Physical Examination
- **Vital Signs:** BP 142/88 mmHg, HR 74 bpm, RR 14, Temp 36.7°C, SpO2 95% RA, BMI 33.2, Waist circumference 112 cm
- **General:** Obese male with central adiposity, appears tired
- **HEENT:** Mallampati class IV, redundant pharyngeal tissue
- **Cardiovascular:** Regular rate and rhythm, no murmurs
- **Respiratory:** Clear bilaterally, no wheeze
- **Abdomen:** Obese, non-tender, no hepatomegaly
- **Genitourinary:** Testes bilaterally descended, slightly soft in consistency, estimated volume 12 mL bilaterally (normal 15-25 mL), no varicocele, no masses, normal penile exam, DRE reveals smooth, mildly enlarged prostate (estimated 35 g) without nodules
- **Musculoskeletal:** Decreased muscle bulk in upper and lower extremities relative to body habitus, increased body fat
- **Skin:** Decreased facial and body hair density, fine periorbital wrinkling
- **Breast:** Mild bilateral gynecomastia (2 cm disc palpable)

### Workup and Results

**Laboratory Studies:**
| Test | Result | Reference Range |
|------|--------|-----------------|
| Total testosterone (8 AM, fasting) | 7.2 nmol/L (208 ng/dL) | 8.7-29.0 nmol/L (250-836 ng/dL) |
| Repeat total testosterone (8 AM) | 7.8 nmol/L (225 ng/dL) | 8.7-29.0 nmol/L |
| Free testosterone (calculated) | 148 pmol/L | 225-725 pmol/L |
| SHBG | 18 nmol/L | 10-57 nmol/L |
| LH | 3.1 IU/L | 1.5-9.3 IU/L |
| FSH | 2.8 IU/L | 1.4-18.1 IU/L |
| Prolactin | 12.4 ng/mL | 2.1-17.7 ng/mL |
| Estradiol | 42 pg/mL | 10-40 pg/mL |
| PSA | 1.2 ng/mL | < 4.0 ng/mL |
| HbA1c | 7.4% | < 5.7% (normal) |
| Fasting glucose | 142 mg/dL | 70-100 mg/dL |
| Fasting insulin | 28.3 mU/L | 2.6-11.1 mU/L |
| Lipid panel | TC 238, LDL 152, HDL 34, TG 260 mg/dL | TC <200, LDL <100, HDL >40, TG <150 |
| CBC | Hgb 13.8 g/dL, Hct 41% | Hgb 13.5-17.5, Hct 38.3-48.6% |
| Hepatic panel | AST 48, ALT 62, GGT 88 U/L | AST <40, ALT <41, GGT <60 |
| DEXA scan | T-score lumbar spine -1.4 | > -1.0 normal |
| Vitamin D | 22 ng/mL | 30-100 ng/mL |

**Imaging/Additional Studies:**
- Pituitary MRI: Normal, no adenoma identified
- Sleep study review: AHI 32 events/hour (severe), lowest SpO2 78%
- Liver ultrasound: Hepatic steatosis (moderate)
- Body composition (DEXA): Total body fat 38%, visceral fat elevated, appendicular lean mass reduced for height (sarcopenic obesity)

### Clinical Image

![Hypothalamic-pituitary-gonadal axis in testosterone deficiency](case_01_image.jpg)

*Diagram of the hypothalamic-pituitary-gonadal (HPG) axis illustrating the pathophysiology of secondary hypogonadism: the negative effects of obesity, sleep apnea, insulin resistance, and alcohol on GnRH and gonadotropin secretion leading to reduced testicular testosterone production. Source: Educational illustration.*

### Diagnosis
**Secondary (Hypogonadotropic) Hypogonadism with Metabolic Syndrome, Uncontrolled Type 2 Diabetes, Severe Untreated Obstructive Sleep Apnea, and Sarcopenic Obesity**

**Key Diagnostic Criteria:**
- Two confirmed early morning total testosterone levels below 8.7 nmol/L (250 ng/dL) with symptoms
- Low-normal LH and FSH indicating secondary (central) etiology
- Low free testosterone with low SHBG (consistent with metabolic syndrome)
- Multiple reversible contributors identified: untreated severe OSA, obesity, uncontrolled diabetes, excessive alcohol, hepatic steatosis
- Mildly elevated estradiol from peripheral aromatization in adipose tissue
- Osteopenia on DEXA (T-score -1.4) likely related to hypogonadism

### Treatment Plan
1. **Address reversible causes first (3-6 month trial before considering TRT):**
   - Mandatory CPAP compliance for severe OSA (AHI 32) with follow-up adherence monitoring; untreated OSA suppresses gonadotropin secretion and is independently associated with low testosterone
   - Alcohol reduction to < 10 units/week with brief motivational counseling; excessive alcohol directly impairs Leydig cell function and increases aromatase activity
   - Structured weight loss program targeting 10% body weight reduction: caloric deficit of 500-750 kcal/day with high-protein intake (1.6 g/kg/day) to preserve lean mass
2. **Diabetes optimization:** Increase metformin to 2000 mg daily if tolerated, add GLP-1 receptor agonist (semaglutide 0.25 mg weekly titrating up) for glycemic control and weight loss
3. **Exercise prescription:** Resistance training 3x/week (compound movements, progressive overload) combined with 150 min/week moderate aerobic activity; resistance training directly stimulates testosterone production
4. **Nutritional intervention:** Mediterranean dietary pattern, reduce refined carbohydrates, zinc 30 mg daily, vitamin D3 5000 IU daily, limit soy-based foods
5. **Reassess testosterone at 3-6 months:** If testosterone remains < 8.7 nmol/L despite optimization of reversible factors, initiate testosterone replacement therapy (testosterone cypionate 100 mg IM weekly or transdermal testosterone gel 50 mg daily) with baseline PSA, hematocrit monitoring
6. **Monitoring if TRT initiated:** PSA and hematocrit at 3, 6, and 12 months, then annually; bone density repeat at 2 years; assess for polycythemia (hematocrit > 54% requires dose reduction or phlebotomy)

### Key Learning Points
- Testosterone deficiency must be confirmed with two early-morning fasting samples, as testosterone levels exhibit diurnal variation with peak levels at 7-9 AM and can be transiently lowered by acute illness, medications, and non-fasting status
- Secondary hypogonadism in obese men is frequently reversible; weight loss of 10-15% can increase testosterone by 2-4 nmol/L, making lifestyle optimization the first-line intervention
- Untreated obstructive sleep apnea suppresses pulsatile GnRH release and is a major reversible cause of hypogonadism that must be addressed before initiating testosterone replacement
- Low SHBG in metabolic syndrome leads to faster testosterone clearance and artificially lowers total testosterone; free testosterone calculation provides more accurate assessment in obese patients
- Testosterone replacement therapy in men with active, untreated severe OSA may worsen apnea; CPAP compliance must be established first

---

## Case 2: Benign Prostatic Hyperplasia with Lower Urinary Tract Symptoms

### Patient Presentation
**Demographics:** 64-year-old male retired teacher

**Chief Complaint:** "I'm up four or five times a night to urinate and I can barely make it to the bathroom during the day."

**History of Present Illness:**
The patient presents with progressive lower urinary tract symptoms (LUTS) that have worsened significantly over the past 18 months. He reports both storage and voiding symptoms. Storage symptoms include nocturia 4-5 times per night (severely disrupting sleep), urinary urgency with occasional urge incontinence (2-3 episodes per week requiring a pad), and frequency of urination every 1-1.5 hours during the day.

Voiding symptoms include hesitancy, a weak and intermittent stream, straining to initiate urination, terminal dribbling, and a sensation of incomplete emptying. He reports that it takes him 2-3 minutes to complete voiding, compared to under a minute previously. He has developed anxiety about long car rides and avoids situations where bathrooms are not immediately accessible.

He denies gross hematuria, dysuria, or perineal pain. He has no history of urinary retention, urinary tract infections, or kidney stones. He tried over-the-counter saw palmetto for 6 months without noticeable improvement.

**Past Medical History:**
- Hypertension (well-controlled)
- Hyperlipidemia
- Osteoarthritis of both knees
- No prior urological history

**Medications:**
- Lisinopril 10 mg daily
- Rosuvastatin 10 mg daily
- Acetaminophen 500 mg PRN for knee pain
- Saw palmetto 320 mg daily

**Social History:**
- Non-smoker, social alcohol (1-2 glasses of wine on weekends)
- Retired, active in community volunteering
- Married, sexually active
- Drinks 3-4 cups of coffee daily, 2 cups of tea in the evening
- Adequate fluid intake (~2.5 L/day)

**Family History:**
- Father: BPH requiring TURP at age 70
- Brother: Prostate cancer diagnosed at 68
- Mother: Hypertension

### Physical Examination
- **Vital Signs:** BP 128/76 mmHg, HR 68 bpm, RR 14, Temp 36.7°C, SpO2 98% RA, BMI 26.8
- **General:** Well-appearing male in no distress
- **Abdomen:** Soft, non-tender, no suprapubic fullness or mass, no costovertebral angle tenderness
- **Genitourinary:** Normal external genitalia, no meatal stenosis, no urethral discharge
- **Digital Rectal Examination:** Prostate symmetrically enlarged (estimated 60-70 g), smooth surface, firm-rubbery consistency, no nodules or induration, median sulcus obliterated, non-tender, normal rectal tone
- **Neurological:** Normal perineal sensation, intact bulbocavernosus reflex, normal lower extremity strength and reflexes

### Workup and Results

**Laboratory Studies:**
| Test | Result | Reference Range |
|------|--------|-----------------|
| Urinalysis | Clear, no blood, no WBCs, no bacteria | Normal |
| Urine culture | No growth | No growth |
| PSA | 3.8 ng/mL | < 4.0 ng/mL (age-adjusted) |
| Free PSA | 28% | > 25% favors benign |
| Creatinine | 1.0 mg/dL | 0.7-1.3 mg/dL |
| eGFR | 78 mL/min/1.73m2 | > 60 mL/min |
| Serum sodium | 140 mEq/L | 136-145 mEq/L |
| Fasting glucose | 96 mg/dL | 70-100 mg/dL |
| HbA1c | 5.4% | < 5.7% |

**Imaging/Additional Studies:**
- IPSS (International Prostate Symptom Score): 24/35 (severe)
- IPSS Quality of Life score: 5/6 (mostly dissatisfied)
- Uroflowmetry: Qmax 8.2 mL/s (normal > 15 mL/s), voided volume 180 mL, flow pattern plateau-shaped
- Post-void residual (PVR): 145 mL (normal < 50 mL, clinically significant > 100 mL)
- Transrectal ultrasound: Prostate volume 68 mL, prominent median lobe protruding into the bladder base, no suspicious lesions
- Renal ultrasound: No hydronephrosis, normal kidney size bilaterally, mild bladder wall thickening (trabeculation)
- Frequency-volume chart (3-day): Average daytime frequency 12, nocturia 4.5, nocturnal polyuria index 38% (normal < 33%), 24-hour urine volume 2.8 L

### Clinical Image

![BPH pathophysiology and prostate zones](case_02_image.jpg)

*Anatomical illustration showing the zonal anatomy of the prostate gland with transition zone hyperplasia in BPH, bladder outlet obstruction mechanics, median lobe enlargement, and resulting detrusor muscle changes including trabeculation and diverticula formation. Source: Educational illustration.*

### Diagnosis
**Benign Prostatic Hyperplasia (BPH) with Moderate-to-Severe Lower Urinary Tract Symptoms (LUTS), Bladder Outlet Obstruction, and Nocturnal Polyuria**

**Key Diagnostic Criteria:**
- IPSS 24/35 (severe symptoms) with significant quality of life impact
- Prostate volume 68 mL with prominent median lobe on TRUS
- Uroflowmetry Qmax 8.2 mL/s confirming obstructive flow pattern
- Elevated PVR of 145 mL indicating incomplete emptying
- Bladder wall trabeculation on ultrasound suggesting detrusor compensation/decompensation
- Nocturnal polyuria index 38% contributing to nocturia
- PSA 3.8 ng/mL with free PSA 28% consistent with benign enlargement (PSA density 0.056 ng/mL/cc)

### Treatment Plan
1. **Combination pharmacotherapy (prostate > 40 mL with severe LUTS):**
   - Alpha-1 adrenergic blocker: tamsulosin 0.4 mg daily (relaxes prostatic smooth muscle for rapid symptom relief within 1-2 weeks)
   - 5-alpha reductase inhibitor: dutasteride 0.5 mg daily (reduces prostate volume by 20-25% over 6-12 months, reduces risk of acute urinary retention and need for surgery)
   - Combination therapy shown in CombAT trial to be superior to either agent alone for prostates > 40 mL
2. **Nocturia management:**
   - Fluid restriction after 6 PM, eliminate evening caffeine (tea)
   - Timed diuretic therapy: furosemide 20 mg in early afternoon to shift fluid mobilization to daytime hours
   - Leg elevation for 30 minutes in late afternoon to reduce peripheral edema redistribution
   - If nocturia persists, consider desmopressin 25 mcg intranasal at bedtime (with sodium monitoring)
3. **Behavioral modifications:**
   - Bladder training with scheduled voiding every 2 hours, gradually increasing intervals
   - Double voiding technique to reduce PVR
   - Reduce caffeine to 1-2 cups before noon only
   - Pelvic floor muscle exercises (male Kegel program)
4. **Discontinue saw palmetto** (insufficient evidence for prostate > 40 mL)
5. **Counseling on 5-ARI side effects:** Discuss potential sexual side effects (decreased libido 2-4%, erectile dysfunction 5-7%, ejaculatory dysfunction 1-2%), inform that PSA will decrease by approximately 50% (double PSA value for cancer screening interpretation)
6. **Follow-up:** IPSS, uroflowmetry, and PVR at 6 weeks (alpha-blocker response), 3 months, 6 months, then annually; PSA at 6 months (new baseline); consider urological referral for minimally invasive therapy (Rezum, UroLift, or Aquablation) if inadequate response at 6 months or patient preference

### Key Learning Points
- Combination therapy with an alpha-blocker plus a 5-alpha reductase inhibitor is the evidence-based standard for men with prostates > 40 mL and moderate-to-severe LUTS, reducing risk of symptom progression, acute retention, and surgical intervention
- Nocturia in older men is often multifactorial: BPH-related storage dysfunction, nocturnal polyuria (from peripheral edema redistribution, reduced nocturnal ADH), and sleep disorders all contribute and should be independently assessed with a frequency-volume chart
- Free PSA percentage helps distinguish benign from malignant causes of PSA elevation; values > 25% strongly favor BPH, while values < 10% raise concern for prostate cancer
- Post-void residual > 100 mL indicates clinically significant incomplete emptying and is a risk factor for urinary retention, UTI, and upper tract damage; serial monitoring is essential
- Median lobe enlargement causes obstructive symptoms disproportionate to overall prostate size and may respond less well to medical therapy, making it an important factor when considering surgical options

---

## Case 3: Male Infertility Evaluation

### Patient Presentation
**Demographics:** 34-year-old male financial analyst

**Chief Complaint:** "My wife and I have been trying to conceive for 18 months without success."

**History of Present Illness:**
The patient and his 31-year-old wife present for male infertility evaluation after 18 months of regular unprotected intercourse without conception. His wife has undergone a gynecological evaluation including hormone levels, pelvic ultrasound, and hysterosalpingography, all of which were normal. They report intercourse 3-4 times per week, with good understanding of the fertile window.

The patient reports normal libido and erectile function. He has no history of prior conceptions or pregnancies with previous partners. He denies any testicular trauma, surgery, or infections including mumps orchitis. He reports a history of bilateral cryptorchidism corrected surgically at age 4 (orchiopexy). He denies any exposure to gonadotoxic medications, radiation, or chemotherapy.

He reports that he works long hours (60+ hours/week) at a desk, frequently uses a laptop on his lap, and uses a hot tub 3-4 times per week for relaxation. He has been under significant work stress for the past 2 years. He exercises regularly with cycling as his primary activity (200+ km/week competitive cycling).

**Past Medical History:**
- Bilateral cryptorchidism (orchiopexy at age 4)
- Varicocele noted incidentally at age 20 (no prior treatment)
- Appendectomy at age 12

**Medications:**
- Testosterone cream 1% applied daily (started 6 months ago from an online men's health clinic for "optimization")
- Finasteride 1 mg daily (for hair loss prevention, started 2 years ago)
- Multivitamin
- Whey protein supplement

**Social History:**
- Non-smoker, social alcohol (4-6 drinks per week)
- Avid cyclist (200+ km/week)
- Regular hot tub use (3-4x/week, 30-minute sessions)
- Uses laptop on lap daily
- Occasional marijuana use (1-2 times per month)
- High-stress work environment

**Family History:**
- Father: Healthy
- Mother: PCOS (required fertility treatment)
- Brother: Conceived naturally without difficulty

### Physical Examination
- **Vital Signs:** BP 118/72 mmHg, HR 62 bpm, RR 14, Temp 36.8°C, SpO2 99% RA, BMI 24.8
- **General:** Athletic, well-developed male
- **Endocrine:** No gynecomastia, normal male hair distribution, no acne
- **Genitourinary:**
  - **Penis:** Normal, circumcised, urethral meatus normally positioned
  - **Right testis:** 15 mL volume (slightly reduced), firm consistency, non-tender, no masses
  - **Left testis:** 14 mL volume (slightly reduced), firm consistency, non-tender, no masses
  - **Left spermatic cord:** Grade II varicocele palpable (increases with Valsalva maneuver), "bag of worms" sensation
  - **Right spermatic cord:** No varicocele
  - **Vas deferens:** Palpable bilaterally
  - **Epididymis:** Non-tender, no fullness bilaterally
- **DRE:** Normal-sized prostate, no abnormalities

### Workup and Results

**Laboratory Studies:**
| Test | Result | Reference Range |
|------|--------|-----------------|
| **Semen Analysis #1** | | |
| Volume | 1.8 mL | > 1.5 mL |
| Concentration | 8 million/mL | > 15 million/mL |
| Total motility | 28% | > 40% |
| Progressive motility | 18% | > 32% |
| Normal morphology (strict) | 2% | > 4% |
| **Semen Analysis #2 (4 weeks later)** | | |
| Volume | 2.0 mL | > 1.5 mL |
| Concentration | 6 million/mL | > 15 million/mL |
| Total motility | 24% | > 40% |
| Progressive motility | 14% | > 32% |
| Normal morphology (strict) | 1% | > 4% |
| Total testosterone | 892 ng/dL | 250-836 ng/dL |
| Free testosterone | 32.4 ng/dL | 5.0-21.0 ng/dL |
| LH | 0.3 IU/L | 1.5-9.3 IU/L |
| FSH | 0.4 IU/L | 1.4-18.1 IU/L |
| Estradiol | 52 pg/mL | 10-40 pg/mL |
| Prolactin | 8.2 ng/mL | 2.1-17.7 ng/mL |
| TSH | 1.8 mIU/L | 0.4-4.0 mIU/L |
| Semen fructose | Present | Present |
| Anti-sperm antibodies | Negative | Negative |
| Sperm DNA fragmentation index | 38% | < 15% excellent, 15-30% good |
| Karyotype | 46,XY | 46,XY |
| Y-chromosome microdeletion | Negative | Negative |

**Imaging/Additional Studies:**
- Scrotal ultrasound: Left varicocele (largest vein 3.8 mm with reflux on Valsalva), both testes slightly reduced volume (right 13.2 mL, left 12.8 mL) with heterogeneous echotexture, no masses, no microlithiasis
- Scrotal Doppler: Elevated left testicular venous reflux confirmed
- Transrectal ultrasound: Normal seminal vesicles and ejaculatory ducts

### Clinical Image

![Male infertility evaluation algorithm](case_03_image.jpg)

*Flowchart illustrating the systematic evaluation of male infertility: from semen analysis abnormalities through hormonal assessment, physical examination findings, and identification of correctable causes including varicocele, exogenous testosterone use, and gonadotoxin exposure. Source: Educational illustration.*

### Diagnosis
**Oligoasthenoteratozoospermia (OAT Syndrome) - Multifactorial Etiology: Exogenous Testosterone-Induced Hypogonadotropic Hypogonadism, Grade II Left Varicocele, Finasteride-Associated Spermatogenic Impairment, Elevated Scrotal Temperature from Lifestyle Factors, and History of Bilateral Cryptorchidism**

**Key Diagnostic Criteria:**
- Two semen analyses confirming oligozoospermia (< 15 million/mL), asthenozoospermia (< 40% motility), and teratozoospermia (< 4% normal morphology)
- Suppressed gonadotropins (LH 0.3, FSH 0.4) with supraphysiologic testosterone indicating exogenous testosterone-induced HPG axis suppression as primary acute cause
- Grade II left varicocele with reflux on Doppler
- Elevated sperm DNA fragmentation index (38%) suggesting oxidative stress damage
- Multiple modifiable risk factors: exogenous testosterone, finasteride, excessive cycling, hot tub exposure, laptop heat exposure

### Treatment Plan
1. **Immediate medication changes (critical):**
   - **Discontinue exogenous testosterone immediately** - this is the most important intervention; exogenous testosterone suppresses intratesticular testosterone (which is 50-100x higher than serum levels) by suppressing LH, leading to spermatogenic arrest; patient education that "testosterone optimization" with exogenous T is an effective male contraceptive
   - **Discontinue finasteride** - 5-alpha reductase inhibitors impair spermatogenesis by blocking conversion of testosterone to DHT, which is required for normal sperm development; effects may take 3-6 months to reverse
2. **HPG axis recovery protocol:**
   - Clomiphene citrate 25 mg every other day to stimulate endogenous LH/FSH recovery and intratesticular testosterone production
   - HCG 1500 IU subcutaneous 3x/week as adjunct to directly stimulate Leydig cells while awaiting pituitary recovery
   - Monitor LH, FSH, testosterone, and estradiol monthly; repeat semen analysis at 3, 6, and 9 months (full spermatogenic cycle is 74 days)
3. **Varicocele repair:**
   - Refer for microsurgical subinguinal varicocelectomy given Grade II varicocele with abnormal semen parameters; meta-analyses demonstrate improvement in semen parameters in 60-80% of men and natural pregnancy rates of 30-40% post-repair
4. **Lifestyle modifications:**
   - Discontinue hot tub use entirely (scrotal hyperthermia reduces spermatogenesis)
   - Reduce cycling to < 100 km/week and use a properly fitted saddle with perineal cutout; avoid cycling in tight clothing
   - Use laptop on desk, not lap (scrotal temperature elevation documented with laptop use)
   - Discontinue marijuana (associated with reduced sperm concentration and motility via endocannabinoid receptor effects on spermatogenesis)
5. **Antioxidant supplementation (for DNA fragmentation):**
   - Coenzyme Q10 200 mg BID, L-carnitine 1000 mg BID, vitamin C 500 mg daily, vitamin E 400 IU daily, zinc 30 mg daily, selenium 200 mcg daily, folic acid 5 mg daily
6. **Follow-up and timeline counseling:**
   - Semen analyses at 3, 6, and 9 months post-intervention (allow minimum 2-3 spermatogenic cycles for improvement)
   - If semen parameters remain severely impaired at 9 months, discuss IVF with ICSI as next step
   - Cryopreserve any improved samples as backup for ART

### Key Learning Points
- Exogenous testosterone administration is a highly effective male contraceptive that suppresses intratesticular testosterone to near-zero levels by eliminating LH drive; it is one of the most common iatrogenic causes of male infertility and is increasingly prescribed by telemedicine clinics without fertility counseling
- Recovery of spermatogenesis after exogenous testosterone cessation typically takes 6-12 months but can take up to 24 months; some men (especially with prolonged use) may not fully recover, making clomiphene and HCG recovery protocols essential
- Finasteride, commonly used for androgenic alopecia, impairs spermatogenesis and should be discontinued in men attempting conception; effects are usually reversible but may persist for months
- Varicocele is the most common correctable cause of male infertility, found in 35-40% of men with primary infertility; microsurgical repair has the best outcomes with lowest recurrence rates
- Sperm DNA fragmentation testing provides prognostic information beyond standard semen analysis and can explain infertility in men with apparently normal or mildly abnormal conventional parameters